Annexon Inc.

21.52-1.90-8.11%Vol 124.61K1Y Perf 21.85%
Apr 19th, 2021 16:00 DELAYED
BID21.52 ASK21.55
Open23.14 Previous Close23.42
Pre-Market- After-Market-
 - -  - -%
Target Price
37.00 
Analyst Rating
— — 0.00
Potential %
71.93 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap821.16M 
Earnings Rating
Price Range Ratio 52W %
27.29 
Earnings Date
29th Mar 2021

Today's Price Range

21.2823.35

52W Range

15.3338.01

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-6.64%
1 Month
-27.86%
3 Months
-18.64%
6 Months
-22.34%
1 Year
21.85%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANNX21.52-1.9000-8.11
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.42-0.61-45.24
Q03 2020-0.34-0.77-126.47
Q02 2020-0.53-28.87-5 347.17
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.42
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume124.61K
Shares Outstanding38.16M
Trades Count2.17K
Dollar Volume3.96M
Avg. Volume162.05K
Avg. Weekly Volume93.35K
Avg. Monthly Volume131.21K
Avg. Quarterly Volume168.72K

Annexon Inc. (NASDAQ: ANNX) stock closed at 21.52 per share at the end of the most recent trading day (a -8.11% change compared to the prior day closing price) with a volume of 124.61K shares and market capitalization of 821.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 38 people. Annexon Inc. CEO is Douglas Love.

The one-year performance of Annexon Inc. stock is 21.85%, while year-to-date (YTD) performance is -14.02%. ANNX stock has a five-year performance of %. Its 52-week range is between 15.33 and 38.01, which gives ANNX stock a 52-week price range ratio of 27.29%

Annexon Inc. currently has a PE ratio of -15.90, a price-to-book (PB) ratio of 2.60, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.66%, a ROC of -13.57% and a ROE of -57.69%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Annexon Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. Annexon Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Annexon Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Annexon Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Annexon Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Annexon Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.03, ATR14 : 2.84, CCI20 : -133.76, Chaikin Money Flow : -0.11, MACD : -1.12, Money Flow Index : 36.79, ROC : -22.70, RSI : 48.34, STOCH (14,3) : 3.39, STOCH RSI : 0.00, UO : 35.17, Williams %R : -96.61), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Annexon Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005; ANX007; and ANX009.

CEO: Douglas Love

Telephone: +1 650 822-5500

Address: 180 Kimball Way, South San Francisco 94080, CA, US

Number of employees: 38

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

71%29%

Bearish Bullish

68%32%

Bearish Bullish

67%33%

News

Stocktwits